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Hyperosmolar lactate-based solutions have been used
for fluid resuscitation in ICU patients. The positive
effects observed with these fluids have been attributed
to both lactate metabolism and the hypertonic
nature of the solutions. In a recent issue of Critical
Care, Duburcq and colleagues studied three types
of fluid infused at the same volume in a porcine
model of endotoxic shock. The control group was
resuscitated with 0.9% NaCl, and the two other
groups received either hypertonic sodium-lactate or
hypertonic sodium-bicarbonate. The two hypertonic
fluids proved to be more effective than 0.9% NaCl
for resuscitation in this model. However, some
parameters were more effectively corrected by
hypertonic sodium-lactate than by hypertonic
sodium-bicarbonate, suggesting that lactate metabolism
was beneficial in these cases.lactate concentrations above 10 mmol/L [3,4]. No sideGlucose is an energy substrate because its catabolism into
CO2 and H2O allows the synthesis of ATP. During this
process, glucose is first converted into pyruvate (glycoly-
sis) before pyruvate enters mitochondria to be further ca-
tabolized (via the citric acid cycle). When pyruvate does
not enter mitochondria, it leaves the cell in which it was
produced to enter another one where it is converted into
glucose (gluconeogenesis) or catabolized to allow ATP
production. Pyruvate can also be converted into lactate in
all cells. Importantly, the reaction is reversible; therefore,
both glucose and lactate can be metabolized into pyru-
vate. Moreover, lactate leaves or enters the cell via the
same transporter as pyruvate. Depending on the distance* Correspondence: eric.fontaine@ujf-grenoble.fr
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them up, pyruvate and lactate travel, or not, in blood.
If from a biochemical point of view pyruvate and lactate
are carbohydrates perfectly usable for ATP production,
their metabolism has some particularities. Compared with
glucose, pyruvate and lactate are easily metabolized by all
tissues even in the case of insulin resistance because insu-
lin does not regulate the pyruvate-lactate transporter.
In ICU patients, both blood glucose [1] and lactate [2]
concentrations positively correlate with the severity of
illness. Does this mean that glucose and lactate worsen
disease in the critically ill? The answer remains uncer-
tain for glucose, considering the efforts made to control
blood glucose in ICU patients. However, this does not
preclude using glucose in the ICU. Is lactate toxic or
harmful? Growing evidence convincingly suggests that
this is not the case. Lactate metabolism has been studied
in both volunteers and patients by measuring lactate
clearance after sodium-lactate loads that increased blood
effects were observed, except an expected alkalinization
and decrease in blood potassium concentration. Indeed,
sodium-lactate has been used instead of sodium-bicarbonate
to treat ventricular tachycardia [5]. Although counterintui-
tive, pioneer studies have shown the harmlessness and
usefulness of sodium-lactate in ICU patients. Hyperosmo-
lar sodium-lactate has been shown (i) to improve cardiac
performance in patients undergoing elective cardiac sur-
gery [6] and during acute heart failure [7]; (ii) to induce a
negative cumulative fluid balance after coronary artery by-
pass grafting [8] and to decrease fluid accumulation dur-
ing burn shock resuscitation [9]; (iii) to be effective in
treating [10] and preventing [11] intracranial hypertension
following severe traumatic brain injury; and (iv) to restore
hemodynamic status in dengue shock syndrome with min-
imal fluid accumulation [12].
The mechanism by which hyperosmolar sodium-lactate
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between these two mechanisms was made. In a recent
study published in Critical Care, Duburcq and colleagues
elegantly discriminated between these two mechanisms
using a porcine model of endotoxic shock [13]. Once
shock had been established, the animals received the same
volume of three different crystalloid-based solutions: 0.9%
NaCl (control group), hyperosmolar sodium-bicarbonate
or hyperosmolar sodium-lactate. Importantly, the hyper-
osmolar groups received the same amount of sodium
and osmoles. Duburcq and colleagues observed that
both hyperosmolar sodium-bicarbonate and hyperos-
molar sodium-lactate prevented anuria and improved
mean pulmonary arterial pressure, mixed venous oxygen
saturation, oxygen extraction and oxygen delivery/global
oxygen consumption ratio better than the control solu-
tion. However, hyperosmolar sodium-lactate improved
mean arterial pressure, microvascular reactivity, arterial
oxygen partial pressure/inspired oxygen fraction ratio,
blood glucose concentration and fluid balance better than
hyperosmolar sodium-bicarbonate and the control solu-
tion. This suggests that some of the positive effects of
hyperosmolar sodium-lactate are due to the hyperosmolar
nature of the solution, while others are directly related to
lactate metabolism.
Both sodium-bicarbonate and sodium-lactate are
metabolizable anions. This means that the negative charge
(bicarbonate or lactate) is converted into uncharged com-
pounds, resulting in sodium load without chloride. In this
respect, sodium-bicarbonate and sodium-lactate are re-
sponsible for similar effects on pH and electrolytes. Con-
trary to bicarbonate, however, lactate is an energy substrate
(3.61 kcal/g). Therefore, future experiments could use
hyperosmolar sodium-bicarbonate supplemented with
another energy substrate (glucose, for example) in order
to further specify whether the advantage of lactate is re-
lated to its particular metabolism or simply to its energy
load.
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